TORONTO, ONTARIO–(Marketwired – March 6, 2017) – BioSyent Inc. (“BioSyent”, “the Company”) (TSX VENTURE:RX) will be reporting its financial results for the fourth quarter and fiscal year ended December 31, 2016 on Wednesday, March 15, 2017. A presentation on the Company’s fourth quarter 2016 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.
As of the date of this press release, the Company has 14,403,553 shares issued and outstanding.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Mr. Rene C. Goehrum
President and CEO